Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Return on Equity (2021 - 2024)

Historic Return on Equity for Immuneering (IMRX) over the last 4 years, with Q3 2024 value amounting to 0.25%.

  • Immuneering's Return on Equity rose 2300.0% to 0.25% in Q3 2024 from the same period last year, while for Sep 2024 it was 0.25%, marking a year-over-year increase of 2300.0%. This contributed to the annual value of 0.55% for FY2023, which is 1700.0% down from last year.
  • Immuneering's Return on Equity amounted to 0.25% in Q3 2024, which was up 2300.0% from 0.39% recorded in Q2 2024.
  • Immuneering's Return on Equity's 5-year high stood at 0.21% during Q4 2021, with a 5-year trough of 0.56% in Q4 2023.
  • For the 4-year period, Immuneering's Return on Equity averaged around 0.4%, with its median value being 0.44% (2022).
  • As far as peak fluctuations go, Immuneering's Return on Equity tumbled by -2300bps in 2023, and later surged by 2300bps in 2024.
  • Over the past 4 years, Immuneering's Return on Equity (Quarter) stood at 0.21% in 2021, then crashed by -104bps to 0.44% in 2022, then dropped by -29bps to 0.56% in 2023, then surged by 55bps to 0.25% in 2024.
  • Its Return on Equity was 0.25% in Q3 2024, compared to 0.39% in Q2 2024 and 0.48% in Q1 2024.